Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Castellano

Showing results (141-150 of 266) with videos related to

Pageof 27
Sort By:
European Urology Oncology|May 15, 2024
Retifanlimab in Advanced Penile Squamous Cell Carcinoma: The Phase 2 ORPHEUS StudyXavier García Del Muro, David Páez López-Bravo, Miler Andrés Cuéllar-Rivas, et al.
European Journal of Cancer (Oxford, England : 1990)|May 17, 2023
Sex differences on multikinase inhibitors toxicity in patients with advanced gastroenteropancreatic neuroendocrine tumoursJorge Hernando, Maria Roca-Herrera, Alejandro García-Álvarez, et al.
Molecular Carcinogenesis|December 19, 2013
PIK3CA gene alterations in bladder cancer are frequent and associate with reduced recurrence in non-muscle invasive tumorsMarta Dueñas, Mónica Martínez-Fernández, Ramón García-Escudero, et al.
BJU International|February 6, 2021
Outcomes of systemic targeted therapy in recurrent renal cell carcinoma treated with adjuvant sunitinibGuillermo de Velasco, Álvaro Ruiz-Granados, Oscar Reig, et al.
The New England Journal of Medicine|October 1, 2019
Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate CancerRonald de Wit, Johann de Bono, Cora N Sternberg, et al.
European Journal of Cancer (Oxford, England : 1990)|September 9, 2020
Safety and efficacy of atezolizumab in patients with autoimmune disease: Subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinomaYohann Loriot, Cora N Sternberg, Daniel Castellano, et al.
Asian Journal of Andrology|October 12, 2019
Prevalence of and risk factors for erectile dysfunction in young nondiabetic obese men: results from a regional studyMarIa Molina-Vega, Maite Asenjo-Plaza, María José Banderas-Donaire, et al.
European Journal of Cancer (Oxford, England : 1990)|August 2, 2011
An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapyViktor Grünwald, Pierre I Karakiewicz, Sevil E Bavbek, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|February 11, 2024
Criteria and indicators to evaluate quality of care in genitourinary tumour boardsJavier Puente, Ferrán Algaba Arrea, Óscar Buisán Rueda, et al.
BMC Cancer|July 4, 2015
Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysisJaume Capdevila, Isabel Sevilla, Vicente Alonso, et al.
Pageof 27

Showing results (141-150 of 266) with videos related to

Sort By:
Pageof 27
European Urology Oncology|May 15, 2024
Retifanlimab in Advanced Penile Squamous Cell Carcinoma: The Phase 2 ORPHEUS StudyXavier García Del Muro, David Páez López-Bravo, Miler Andrés Cuéllar-Rivas, et al.
European Journal of Cancer (Oxford, England : 1990)|May 17, 2023
Sex differences on multikinase inhibitors toxicity in patients with advanced gastroenteropancreatic neuroendocrine tumoursJorge Hernando, Maria Roca-Herrera, Alejandro García-Álvarez, et al.
Molecular Carcinogenesis|December 19, 2013
PIK3CA gene alterations in bladder cancer are frequent and associate with reduced recurrence in non-muscle invasive tumorsMarta Dueñas, Mónica Martínez-Fernández, Ramón García-Escudero, et al.
BJU International|February 6, 2021
Outcomes of systemic targeted therapy in recurrent renal cell carcinoma treated with adjuvant sunitinibGuillermo de Velasco, Álvaro Ruiz-Granados, Oscar Reig, et al.
The New England Journal of Medicine|October 1, 2019
Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate CancerRonald de Wit, Johann de Bono, Cora N Sternberg, et al.
European Journal of Cancer (Oxford, England : 1990)|September 9, 2020
Safety and efficacy of atezolizumab in patients with autoimmune disease: Subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinomaYohann Loriot, Cora N Sternberg, Daniel Castellano, et al.
Asian Journal of Andrology|October 12, 2019
Prevalence of and risk factors for erectile dysfunction in young nondiabetic obese men: results from a regional studyMarIa Molina-Vega, Maite Asenjo-Plaza, María José Banderas-Donaire, et al.
European Journal of Cancer (Oxford, England : 1990)|August 2, 2011
An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapyViktor Grünwald, Pierre I Karakiewicz, Sevil E Bavbek, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|February 11, 2024
Criteria and indicators to evaluate quality of care in genitourinary tumour boardsJavier Puente, Ferrán Algaba Arrea, Óscar Buisán Rueda, et al.
BMC Cancer|July 4, 2015
Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysisJaume Capdevila, Isabel Sevilla, Vicente Alonso, et al.
Pageof 27